LEAD Therapeutics, Inc., has established a two-way strategic research collaboration with ShangPharma of China. The investment division of ShangPharma, China Gateway Life Science (Holding) Ltd., will make an equity investment of unspecified size in LEAD Therapeutics. LEAD Therapeutics will turn around and use a division of ShangPharma as the CRO for its drug development projects, providing 20 to 30 scientists who will work exclusively on LEAD's projects.  More details...

Stock Symbol: (NYSE: LLY)